Maplirpacept
- Generic Name
- Maplirpacept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 44D51T6SZH
- Background
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT05896774
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05675449
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center - Aventura, Aventura, Florida, United States
🇺🇸Johns Hopkins Medicine, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT05626322
- Locations
- 🇺🇸
LSU Health Baton Rouge North Clinic, Baton Rouge, Louisiana, United States
🇺🇸Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸Thompson Cancer Survival Center, Knoxville, Tennessee, United States
TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Recurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated with Chronic InflammationRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 62
- Registration Number
- NCT05507541
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.